Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy

Sivaraman, A; Ordaz Jurado, G; Cathelineau, X; Barret, Eric; Dell'Oglio, P; Joniau, S; Bianchi, M; Briganti, A; Spahn, Martin; Bastian, P; Chun, J; Chlosta, P; Gontero, P; Graefen, M; Jeffrey Karnes, R; Marchioro, G; Tombal, B; Tosco, L; van der Poel, H Henk and Sanchez-Salas, R (2016). Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. World journal of urology, 34(10), pp. 1367-1372. Springer 10.1007/s00345-016-1784-8

Preview

Text art%3A10.1007%2Fs00345-016-1784-8.pdf - Published Version Available under License Publisher holds Copyright. Download (772kB) | Preview

INTRODUCTION

The aim of the study was to identify the appropriate level of Charlson comorbidity index (CCI) in older patients (>70 years) with high-risk prostate cancer (PCa) to achieve survival benefit following radical prostatectomy (RP).

METHODS

We retrospectively analyzed 1008 older patients (>70 years) who underwent RP with pelvic lymph node dissection for high-risk prostate cancer (preoperative prostate-specific antigen >20 ng/mL or clinical stage ≥T2c or Gleason ≥8) from 14 tertiary institutions between 1988 and 2014. The study population was further grouped into CCI < 2 and ≥2 for analysis. Survival rate for each group was estimated with Kaplan-Meier method and competitive risk Fine-Gray regression to estimate the best explanatory multivariable model. Area under the curve (AUC) and Akaike information criterion were used to identify ideal 'Cut off' for CCI.

RESULTS

The clinical and cancer characteristics were similar between the two groups. Comparison of the survival analysis using the Kaplan-Meier curve between two groups for non-cancer death and survival estimations for 5 and 10 years shows significant worst outcomes for patients with CCI ≥ 2. In multivariate model to decide the appropriate CCI cut-off point, we found CCI 2 has better AUC and p value in log rank test.

CONCLUSION

Older patients with fewer comorbidities harboring high-risk PCa appears to benefit from RP. Sicker patients are more likely to die due to non-prostate cancer-related causes and are less likely to benefit from RP.

Interest & Impact

Downloads

24 since deposited on 08 Jun 2016
24 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item